Dr. Armstrong received his B.S. from Alma College in 2000 where he graduated with Honors in Exercise & Health Science and was recognized as a 1st Team Academic All-American in football. Dr. Armstrong earned a prestigious NCAA Post-graduate Scholarship and went on to study at the University of Illinois-Chicago, in the lab of Dr. Karyn Esser. Dr. Armstrong completed his PhD studies while researching the molecular mechanisms of skeletal muscle hypertrophy. In 2005, Dr. Armstrong joined the global biopharmaceutical company Novartis and studied the epigenetic regulation of endogenous muscle stem cells. In 2008, Dr. Armstrong founded the biotech startup 4s3 Bioscience, now Valerion Therapeutics. As Chief Scientific Officer, Dr. Armstrong has led the preclinical development of Valerion’s pipeline of therapeutic Antibody-Enzyme Fusions; including, the lead clinical candidate, VAL-1221, currently being tested in a Phase I/II trial for Pompe disease. Dr. Armstrong is the inventor of numerous scientific patents, primary investigator of several awarded patient foundation and government grants, and a recently invited Scientific Advisor to the Keystone Conference.